EF Hutton Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and set a price target of $21.
August 13, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Annovis Bio with a Buy rating and a price target of $21, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $21 by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100